Skip to main content

Melissa B. Daluvoy

Associate Professor of Ophthalmology
Ophthalmology, Corneal Diseases
2351 Erwin Rd, Durham, NC 27705

Overview


Melissa B. Daluvoy, MD, is a fellowship trained, board-certified ophthalmologist, with expertise in the medical and surgical treatment of cornea and anterior segment diseases. She performs routine and complex cataract surgeries and offers astigmatism and presbyopia correcting intraocular lenses.

She specializes in advanced corneal transplantation procedures including PK, DSEK, DALK and keratoprosthesis. She performs other anterior segment procedures (Intacs, ptyergia excisions, etc.) as well as refractive surgeries including custom bladeless Intralase LASIK, PRK, PTK and phakic intraocular lenses (implantable contact lenses). She has a special interest in the management of ocular surface diseases like dry eye and blepharitits; and she offers the new Lipiflow procedure.

Dr. Daluvoy is dedicated to delivering personalized treatment while providing high level patient care. She has several publications and is a member of the American Academy of Ophthalmology and American Society of Cataract and Refractive Surgery.

Dr. Daluvoy lives in Durham with her family and is an avid runner.

Current Appointments & Affiliations


Associate Professor of Ophthalmology · 2021 - Present Ophthalmology, Corneal Diseases, Ophthalmology
Chief, Corneal Ophthalmology · 2025 - Present Ophthalmology, Corneal Diseases, Ophthalmology

Recent Publications


Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · April 1, 2025 IMPORTANCE: High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. OBJECTIVE: To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or wo ... Full text Link to item Cite

Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · April 1, 2025 IMPORTANCE: Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. OBJECTIVE: To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, s ... Full text Link to item Cite
View All Publications

Recent Grants


CAM-101

Clinical TrialPrincipal Investigator · Awarded by Cambium · 2018 - 2020

View All Grants

Education, Training & Certifications


Thomas Jefferson University, Sidney Kimmel Medical College · 2005 M.D.
The University of Scranton · 2001 M.P.T.
The University of Scranton · 2000 B.S.